{"id":"mpv-a-vaccine-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine works by presenting antigens from multiple pathogens to the immune system, triggering both humoral (antibody-mediated) and cellular immune responses. This approach aims to generate protective immunity against the targeted pathogens, potentially reducing infection rates or disease severity in vaccinated populations.","oneSentence":"MPV-A is a multi-pathogen vaccine designed to provide immunological protection against multiple viral pathogens through stimulation of adaptive immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:17.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of multiple viral infections (specific pathogens not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT04450498","phase":"PHASE4","title":"A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years","status":"COMPLETED","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2020-12-23","conditions":"Neisseria Meningitides Meningitis","enrollment":260},{"nctId":"NCT02003495","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2013-10","conditions":"Meningitis","enrollment":2195}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Group A Meningococcal Polysaccharide vaccine"],"phase":"phase_3","status":"active","brandName":"MPV-A Vaccine Group","genericName":"MPV-A Vaccine Group","companyName":"Beijing Minhai Biotechnology Co., Ltd","companyId":"beijing-minhai-biotechnology-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"MPV-A is a multi-pathogen vaccine designed to provide immunological protection against multiple viral pathogens through stimulation of adaptive immune responses. Used for Prevention of multiple viral infections (specific pathogens not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}